506780503 07/22/2021

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT6827320

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
NAVITOR PHARMACEUTICALS, INC.	03/29/2021

RECEIVING PARTY DATA

Name:	ANAKURIA THERAPEUTICS, INC.	
Street Address:	1030 MASSACHUSETTS AVENUE, SUITE 410	
City:	CAMBRIDGE	
State/Country:	MASSACHUSETTS	
Postal Code:	02138	

PROPERTY NUMBERS Total: 11

Property Type	Number
Application Number:	62217372
Application Number:	15758861
Application Number:	16443298
Application Number:	17104771
Application Number:	62685666
Application Number:	17111674
Application Number:	62944166
Application Number:	63140523
Application Number:	63202524
PCT Number:	US2020063351
PCT Number:	US2019037507

CORRESPONDENCE DATA

506780503

Fax Number: (617)275-8374

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 6177287100

Email: BOSPatents@dechert.com

Correspondent Name: DECHERT LLP

Address Line 1: ONE INTERNATIONAL PLACE, 40TH FLOOR

Address Line 2: 100 OLIVER STREET

Address Line 4: BOSTON, MASSACHUSETTS 02110-2605

REEL: 056948 FRAME: 0187

PATENT

ATTORNEY DOCKET NUMBER:	393499-142344	
NAME OF SUBMITTER: ANDREA L.C. REID		
SIGNATURE:	/Andrea L.C. Reid/	
DATE SIGNED: 07/22/2021		
Total Attachments: 4		
source=Assignment_Navitor_Anakuria#page1.tif		

source=Assignment_Navitor_Anakuria#page1.tif source=Assignment_Navitor_Anakuria#page2.tif source=Assignment_Navitor_Anakuria#page3.tif source=Assignment_Navitor_Anakuria#page4.tif

> PATENT REEL: 056948 FRAME: 0188

CONFIRMATION OF ASSIGNMENT

WHEREAS, we, the undersigned, NAVITOR PHARMACEUTICALS, INC., having a place of business at 1030 Massachusetts Avenue, Suite 410, Cambridge, Massachusetts 02138, USA, (hereinafter termed "Assignor"), owner of the entire right, title and interest in and to certain new and useful improvements disclosed in the patents and applications listed on Annex A hereto (collectively, the "Assigned Patents"), by virtue of a prior assignments from inventors David John O'NEILL, Eddine SAIAH, and Seong Woo Anthony KANG (hereinafter termed "Inventors"), and in and to all embodiments of the inventions, heretofore conceived, made or discovered by said Inventors (all collectively hereinafter termed "said inventions"), and in and to any and all patents, inventor's certificates and other forms of protection (hereinafter termed "Assigned Patents") thereon granted in the United States and foreign countries;

WHEREAS, ANAKURIA THERAPEUTICS, INC., having a place of business at 1030 Massachusetts Avenue, Suite 410, Cambridge, Massachusetts 02138, USA (hereinafter termed "Assignee"), is desirous of acquiring Assignor's entire right, title and interest in and to said Assigned Patents and the inventions disclosed therein, and in and to all embodiments of the inventions, heretofore conceived, made or discovered by said Inventors (all collectively hereinafter termed "said inventions"), and in and to any and all patents, inventor's certificates and other forms of protection (hereinafter termed "Assigned Patents") thereon granted in the United States and foreign countries.

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Assignor to have been received in full from said Assignee:

- 1. Said Assignor does hereby sell, assign, transfer and convey, and/or confirm prior sale, assignments, transfer, and conveyance, unto said Assignee, Assignor's entire right, title and interest (a) in and to said Assigned Patents and said inventions; (b) in and to all rights to apply for foreign patents on said inventions pursuant to the International Convention for the Protection of Industrial Property or otherwise; (c) in and to any and all applications filed and any and all patents granted on said inventions in the United States or any foreign country, including each and every application filed and each and every patent granted on any application which is a division, substitution, or continuation of any of said Assigned Patents; and (d) in and to each and every reissue or extensions of any of said patents.
- 2. Said Assignor hereby covenants and agrees to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right title and interest herein conveyed in the United States and foreign countries. Such cooperation by said Assignor shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any of said applications; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said invention; (d) for filing and prosecuting applications for reissuance of any said patents; (e) for interference or other priority proceedings involving said invention; and (f) for legal proceedings involving said invention and any applications therefore and any patents granted thereon, including without limitation opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that the expense incurred by said Assignor in providing such cooperation shall be paid for by said Assignee.
- 3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said Assignor, their respective heirs, legal representatives and assigns.
- 4. Said Assignor hereby warrants and represents that he has not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

PATENT 27712422.1.BUSINESS REEL: 056948 FRAME: 0189 The undersigned, whose title is supplied below, is authorized to act on behalf of the assignor.

Assignor: Navitor Pharmaceuticals, Inc.

Date: March 29, 2021 Signed:

Print Name: Rick Lundberg

Print Title: SVP; Corporate Secretary & Treasurer

Address: 1030 Massachusetts Avenue, Suite 410,

Cambridge, Massachusetts 02138, USA

Assignee: <u>Anakuria Therapeutics, Inc.</u>

Print Name: Rick Lundberg

Signed:

Date:

March 29, 2021

Print Title: Corporate Secretary & Treasurer

Address: 1030 Massachusetts Avenue, Suite 410

Cambridge, Massachusetts 02138

USA

Page 2 of 4

ANNEX A

THE ASSIGNED PATENT APPLICATIONS

Dechert Reference	Country	Application Number	Title
393499-001USP1 (143062)	United States	US 62/217,372	RAPAMYCIN ANALOGS AND USES THEREOF
393499-001US (159709)	United States	US 15/758,861	RAPAMYCIN ANALOGS AND USES THEREOF
393499-001WO (148541)	PCT	PCT/US2016/050913	RAPAMYCIN ANALOGS AND USES THEREOF
393499-008AU (177732)	Australia	2019286524	RAPAMYCIN ANALOGS AND USES THEREOF
393499-008BR (177733)	Brazil	BR112020025283-2	RAPAMYCIN ANALOGS AND USES THEREOF
393499-008CA (177734)	Canada	3,103,282	RAPAMYCIN ANALOGS AND USES THEREOF
393499-008CN (177735)	China	201980047384.3	RAPAMYCIN ANALOGS AND USES THEREOF
393499-008CO (177736)	Colombia	NC2020/0015747	RAPAMYCIN ANALOGS AND USES THEREOF
393499-008EA (177737)	Eurasia	202092692	RAPAMYCIN ANALOGS AND USES THEREOF
393499-008EP (177738)	Europe	19819402.9	RAPAMYCIN ANALOGS AND USES THEREOF
393499-008IL (177739)	Israel	279329	RAPAMYCIN ANALOGS AND USES THEREOF
393499-008IN (177740)	India	202017054625	RAPAMYCIN ANALOGS AND USES THEREOF
393499-008JP (177741)	Japan	2020-569883	RAPAMYCIN ANALOGS AND USES THEREOF
393499-008KR (177742)	Korea	10-2021-7001301	RAPAMYCIN ANALOGS AND USES THEREOF
393499-008MX (177743)	Mexico	MX/a/2020/013630	RAPAMYCIN ANALOGS AND USES THEREOF

Page 3 of 4

PATENT 27712422.1.BUSINESS REEL: 056948 FRAME: 0191

Dechert Reference	Country	Application Number	Title
393499-008NZ (177744)	New Zealand	770840	RAPAMYCIN ANALOGS AND USES THEREOF
393499-008SG (177745)	Singapore	11202012447Y	RAPAMYCIN ANALOGS AND USES THEREOF
393499-008US (166840)	United States	16/443,298	RAPAMYCIN ANALOGS AND USES THEREOF
393499-008USD1 (177585)	United States	17/104,771	RAPAMYCIN ANALOGS AND USES THEREOF
393499-008USP1 (160620)	United States	62/685,666	RAPAMYCIN ANALOGS AND USES THEREOF
393499-008WO (166841)	PCT	PCT/US2019/037507	RAPAMYCIN ANALOGS AND USES THEREOF
393499-008ZA (177636)	South Africa	2020/07764	RAPAMYCIN ANALOGS AND USES THEREOF
393499-013TW (177596)	Taiwan	109142952	RAPAMYCIN ANALOGS AND USES THEREOF
393499-013US (177595)	United States	17/111,674	RAPAMYCIN ANALOGS AND USES THEREOF
393499-013USP1 (168373)	United States	62/944,166	RAPAMYCIN ANALOGS AND USES THEREOF
393499-013WO (177597)	PCT	PCT/US2020/063351	RAPAMYCIN ANALOGS AND USES THEREOF
393499-014USP1 (177868)	United States	63/140,523	RAPAMYCIN ANALOGS AND USES THEREOF
393499-014USP2 (182183)	United States	63/202,524	RAPAMYCIN ANALOGS AND USES THEREOF

PATENT 27712422.1.BUSINESS REEL: 056948 FRAME: 0192 Page 4 of 4

RECORDED: 07/22/2021